What is it about?
Highlight: RAPID3 is a simple clinical tool to measure disease activity in Rheumatoid Arthritis (RA). It consumes much less time than the formal joint count and can be used in busy clinical settings to make treatment decisions as it correlates well with DAS28 and CDAI, the standard composite scores used to measure disease activity in RA.
Featured Image
Why is it important?
Unlike DAS28 and CDAI, the composite activity scores that include formal joints and/or laboratory parameters, RAPID3 is based on patient reported outcome measures and physician's global assessment. Hence, it is less time consuming and can be used in busy clinical settings. Moreover, it doesn't require any laboratory testing. This study found good correlation between RAPID3 and DAS28, and between RAPID3 and CDAI, hence, validating the results of previous studies.
Perspectives
We conclude that RAPID3 has a strong correlation with DAS28 and CDAI. Since it is less time consuming and doesn't require any laboratory testing, it may be used in place of DAS28 and CDAI in monitoring patients with Rheumatoid Arthritis.
Dr Vikas Gupta
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Read the Original
This page is a summary of: Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience, Clinical Rheumatology, September 2012, Springer Science + Business Media,
DOI: 10.1007/s10067-012-2070-9.
You can read the full text:
Contributors
The following have contributed to this page
